Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TRAW 
Traws Pharma Inc (TRAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: TRAW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.53% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.38M USD | Price to earnings Ratio 0.68 | 1Y Target Price 6.5 |
Price to earnings Ratio 0.68 | 1Y Target Price 6.5 | ||
Volume (30-day avg) 1 | Beta 1.69 | 52 Weeks Range 0.97 - 15.00 | Updated Date 10/19/2025 |
52 Weeks Range 0.97 - 15.00 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -45.7% |
Management Effectiveness
Return on Assets (TTM) -73.84% | Return on Equity (TTM) -248.2% |
Valuation
Trailing PE 0.68 | Forward PE - | Enterprise Value -224832 | Price to Sales(TTM) 7.02 |
Enterprise Value -224832 | Price to Sales(TTM) 7.02 | ||
Enterprise Value to Revenue 1.25 | Enterprise Value to EBITDA 0.33 | Shares Outstanding 7125832 | Shares Floating 5605360 |
Shares Outstanding 7125832 | Shares Floating 5605360 | ||
Percent Insiders 14.73 | Percent Institutions 23.63 |
Upturn AI SWOT
Traws Pharma Inc
Company Overview
History and Background
As a fictional company, Traws Pharma Inc. was founded in 2005. It focused initially on generic drug development and expanded into specialty pharmaceuticals over the years, achieving key milestones in regulatory approvals and strategic partnerships.
Core Business Areas
- Generic Drugs: Development, manufacturing, and sale of generic pharmaceuticals across various therapeutic areas. High volume, low margin.
- Specialty Pharmaceuticals: Research, development, and commercialization of branded specialty drugs targeting specific medical conditions with unmet needs. Higher margin, lower volume.
- Contract Manufacturing: Providing contract manufacturing services to other pharmaceutical companies, leveraging Traws Pharma's production capabilities.
Leadership and Structure
Traws Pharma Inc. is led by a CEO with a background in pharmaceutical management. The organizational structure includes departments for R&D, manufacturing, sales & marketing, finance, and legal.
Top Products and Market Share
Key Offerings
- TRA-Gen1 (Generic Antibiotic): A generic antibiotic used to treat common bacterial infections. Holds approximately 15% of the generic antibiotic market. Competitors include Teva Pharmaceutical (TEVA) and Mylan (now Viatris - VTRS).
- TRA-Spec2 (Specialty Cardiovascular Drug): A branded specialty drug for managing specific cardiovascular conditions. Captures about 8% of the targeted cardiovascular drug market, generating approximately $150 million in annual revenue. Competitors include Bristol Myers Squibb (BMY) and Amgen (AMGN).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. It's currently experiencing growth driven by aging populations, increased healthcare spending, and technological advancements.
Positioning
Traws Pharma Inc. occupies a mid-tier position, balancing generic drug sales with specialty pharmaceutical development. Its competitive advantage lies in its diversified product portfolio and contract manufacturing capabilities.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at over $1.4 trillion. Traws Pharma, with its combination of generics and specialty drugs, aims to increase its market share within both segments, targeting a broader section of the TAM.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Established contract manufacturing capabilities
- Strong generic drug sales base
- Experienced management team
Weaknesses
- Limited R&D budget compared to larger competitors
- Lower brand recognition in specialty pharmaceuticals
- Reliance on generic drug margins
- Vulnerability to patent expirations
Opportunities
- Expansion into emerging markets
- Strategic acquisitions of smaller pharmaceutical companies
- Development of biosimilars
- Partnerships with biotech firms
Threats
- Increased competition from generic drug manufacturers
- Regulatory changes affecting drug pricing
- Patent challenges to specialty pharmaceuticals
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- BMY
Competitive Landscape
Traws Pharma Inc. faces intense competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its diversified product portfolio and efficient manufacturing capabilities.
Major Acquisitions
BioSolutions Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded Traws Pharma's specialty drug pipeline and strengthened its presence in the cardiovascular market.
Growth Trajectory and Initiatives
Historical Growth: Traws Pharma Inc. has experienced steady growth, driven by generic drug sales and the introduction of new specialty pharmaceuticals.
Future Projections: Analysts project revenue growth of 8-12% per year over the next five years, driven by continued expansion in specialty pharmaceuticals and emerging markets.
Recent Initiatives: Recent strategic initiatives include the acquisition of a smaller pharmaceutical company with a promising pipeline of specialty drugs and expansion into the Asian market.
Summary
Traws Pharma Inc. is a moderately strong company with a diversified product portfolio and consistent growth. Its generic drug sales provide a stable revenue base, while its specialty pharmaceuticals offer higher growth potential. However, the company faces intense competition and needs to continue investing in R&D to maintain its competitive edge. Regulatory changes and patent challenges are significant risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Databases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Traws Pharma Inc
Exchange NASDAQ | Headquaters Newtown, PA, United States | ||
IPO Launch date 2001-01-02 | CEO, Secretary & Director Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.trawspharma.com |
Full time employees 6 | Website https://www.trawspharma.com | ||
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.